- Home
- HPP vs ZBIO Comparison
HPP vs ZBIO Comparison
Compare HPP & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- ZBIO
- Stock Information
- Founded
- HPP 2009
- ZBIO 2019
- Country
- HPP United States
- ZBIO United States
- Employees
- HPP N/A
- ZBIO N/A
- Industry
- HPP Real Estate
- ZBIO
- Sector
- HPP Finance
- ZBIO
- Exchange
- HPP Nasdaq
- ZBIO NYSE
- Market Cap
- HPP 420.6M
- ZBIO 339.3M
- IPO Year
- HPP 2010
- ZBIO 2024
- Fundamental
- Price
- HPP $3.17
- ZBIO $8.40
- Analyst Decision
- HPP Hold
- ZBIO Strong Buy
- Analyst Count
- HPP 11
- ZBIO 5
- Target Price
- HPP $4.75
- ZBIO $31.75
- AVG Volume (30 Days)
- HPP 6.1M
- ZBIO 371.9K
- Earning Date
- HPP 02-20-2025
- ZBIO 02-16-2025
- Dividend Yield
- HPP 3.17%
- ZBIO N/A
- EPS Growth
- HPP N/A
- ZBIO N/A
- EPS
- HPP N/A
- ZBIO N/A
- Revenue
- HPP $847,713,000.00
- ZBIO N/A
- Revenue This Year
- HPP N/A
- ZBIO N/A
- Revenue Next Year
- HPP $0.04
- ZBIO N/A
- P/E Ratio
- HPP N/A
- ZBIO N/A
- Revenue Growth
- HPP N/A
- ZBIO N/A
- 52 Week Low
- HPP $2.39
- ZBIO $7.50
- 52 Week High
- HPP $9.25
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- HPP 54.13
- ZBIO N/A
- Support Level
- HPP $2.84
- ZBIO N/A
- Resistance Level
- HPP $3.04
- ZBIO N/A
- Average True Range (ATR)
- HPP 0.19
- ZBIO 0.00
- MACD
- HPP 0.08
- ZBIO 0.00
- Stochastic Oscillator
- HPP 74.26
- ZBIO 0.00
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.